Blue Trust Inc. Sells 1,536 Shares of Doximity, Inc. (NASDAQ:DOCS)

Blue Trust Inc. decreased its holdings in Doximity, Inc. (NASDAQ:DOCS) by 53.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,334 shares of the company’s stock after selling 1,536 shares during the period. Blue Trust Inc.’s holdings in Doximity were worth $71,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Shaker Investments LLC OH purchased a new position in shares of Doximity during the fourth quarter worth approximately $559,000. Fountainhead AM LLC purchased a new position in shares of Doximity during the third quarter worth approximately $710,000. Penserra Capital Management LLC purchased a new position in shares of Doximity during the third quarter worth approximately $2,384,000. Newbridge Financial Services Group Inc. purchased a new position in shares of Doximity during the fourth quarter worth approximately $362,000. Finally, Stratos Wealth Partners LTD. purchased a new position in Doximity during the fourth quarter valued at approximately $203,000. Institutional investors own 87.19% of the company’s stock.

Doximity Stock Down 3.7 %

DOCS stock opened at $72.25 on Monday. Doximity, Inc. has a 52-week low of $22.96 and a 52-week high of $85.21. The stock has a market capitalization of $13.49 billion, a price-to-earnings ratio of 72.25, a price-to-earnings-growth ratio of 4.10 and a beta of 1.39. The stock’s fifty day simple moving average is $60.19 and its 200-day simple moving average is $49.38.

Analysts Set New Price Targets

DOCS has been the topic of several research reports. Stephens assumed coverage on shares of Doximity in a report on Friday, December 20th. They set an “equal weight” rating and a $55.00 price objective on the stock. Canaccord Genuity Group downgraded shares of Doximity from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $40.00 to $60.00 in a research note on Wednesday, November 13th. Needham & Company LLC boosted their target price on shares of Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Leerink Partners upgraded shares of Doximity from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Finally, Bank of America boosted their target price on shares of Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $64.22.

Insider Activity at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company’s stock, valued at $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 37.40% of the stock is owned by insiders.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.